Michael G. King

Novocure Ltd (NASDAQ: NVCR) shares have surged 10 percent since October 10, while remaining meaningfully below the high end of their 52-week range of $15.01 - $30.89. JMP Securities’ Michael G. King initiated coverage of the company with an Outperform rating and a price target of $43...

Amid a flood of news from smaller bio-pharmaceutical concerns, analysts at JMP Securities picked through some winners and losers. The firm's analysts maintained Outperform ratings Wednesday on Infinity Pharmaceuticals Inc. (NASDAQ: INFI), Impax Laboratories Inc (NASDAQ: IPXL) and...

In a report published Tuesday, JMP Securities named three biotech stocks it is watching: Acceleron Pharma Inc (NASDAQ: XLRN), Cardiovascular Systems Inc (NASDAQ: CSII) and Karyopharm Therapeutics Inc (NASDAQ: KPTI). Acceleron’s (Market Outperform, $52 price target) early stage...

Four companies in the healthcare and pharmaceuticals sectors posted mixed results that left analysts at JMP Securities mostly feeling good. Adeptus Health Inc's (NYSE: ADPT) closed Friday up nearly 2 percent on strong quarterly results. JMP analyst Peter L. Martin expects Adeptus shares...

In a report published Monday, JMP Securities analyst Michael G. King initiated coverage on Ardelyx (NASDAQ: ARDX) with a Market Outperform rating and $26.00 price target. In the report, JMP Securities noted, “Initiating coverage of Ardelyx, the industry leader in the development of non-absorbed...

In a report published Thursday, JMP Securities analyst Michael G. King reiterated a Market Outperform rating and $30.00 price target on BIND Therapeutics (NASDAQ: BIND). In the report, JMP Securities noted, “BIND Therapeutics announces the close of its Accurin nanomedicine collaboration with Amgen...

In a report published Monday, JMP Securities analyst Michael G. King reiterated a Market Outperform rating on Navidea Biopharmaceuticals (NYSE: NAVB), but lowered the price target from $5.00 to $3.00. In the report, JMP Securities noted, “Navidea Biopharmaceuticals reprioritizes its pipeline away...

In a report published Thursday, JMP Securities analyst Michael G. King reiterated a Market Outperform rating on Acceleron Pharma (NASDAQ: XLRN), and raised the price target from $32.00 to $36.00. In the report, JMP Securities noted, “We reiterate our Market Outperform rating on Acceleron Pharma...

In a report published Tuesday, JMP Securities analyst Michael G. King initiated coverage on BIND Therapeutics (NASDAQ: BIND) with a Market Outperform rating and $30.00 price target. In the report, JMP Securities noted, “Initiating coverage of BIND Therapeutics with a Market Outperform rating and...

Shares of pharmaceutical company Depomed, Inc. (Nasdaq: DEPO) fell today, amid FDA concerns and an analyst downgrade. The bad news began when fellow drugmaker XenoPort, Inc. (Nasdaq: XNPT) received a letter from the FDA stating that the company would not approve its gabapentin encarbil drug called...